Chimeric antigen receptors (CARs) targeting hematologic malignancies, compositions and methods of use thereof
AssigneeiCell Gene Therapeutics Inc.
InventorsYupo Ma, Kevin Pinz, Xun Jiang, Masayuki Wada, Kevin Chen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides chimeric anti-gen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the poly-nucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.
Claims3
A method of treating T-cell acute lymphoblastic leukemia (T-ALL) in a patient in need thereof, wherein said method comprises administering to said patient an engineered cell expressing a polypeptide comprising a chimeric antigen receptor polypeptide (CAR), where the CAR comprises a signal peptide, an antigen recognition domain, a hinge region, a transmembrane domain, at least one co-stimulatory domain, and a signaling domain and wherein the antigen recognition domain is selective for CD7.
Dependencies are inferred from the claim text.